Eric Bass, MS

Eric Bass is a seasoned professional with a remarkable 25+ year career spanning academia, industry, and consulting in the specialized domain of clinical trials. In 2010, he assumed the role of Principal Biostatistician at NAMSA, progressing to his current position as Director of Global Data Sciences. Within NAMSA, Eric provides strategic leadership in biostatistics, statistical programming, data management, and database development. His academic journey began with a BA from the University of Minnesota, Morris, followed by an MS in Statistics from Texas A&M. Eric’s extensive experience and academic rigor have made him an invaluable asset in steering clinical trial excellence and innovation at NAMSA.

CORE COMPETENCIES

• Sample size calculations, study design, endpoint definition, and biostatistical contributions to investigational plans
• Global regulatory interactions, negotiation of study design, and interpretation of statistical results
• Analyzing and reporting clinical trial data for multiple high-profile studies including PMA submissions and multiple international trials
• Providing tables, graphics, and statistical knowledge for scientific conference presentations and journal publications – including co-authorship in the New England Journal of Medicine
• Authoring and executing statistical analysis plans and report templates
• Consulting with medical, marketing, investigators, and Sponsors on analysis plans and explained results
• Establishing automated daily reports via an internal webpage and e-mail to create an infrastructure on a large diagnostic trial

• Survey research, retrospective studies, epidemiologic studies, QoL data, cancer clinical trials, and medical device trials
• Efficient lead and validation programming
• Project timeline development and execution

• Assisting with design of Case Report Forms and creation of Oracle Clinical and Medidata EDC databases
• Evaluating data reliability and integrity

RECENT PROJECTS

• Lead statistician on international cardiovascular study of a drug eluting stent
• Led Biostatistics and Data Management departments involved in 100+ clinical studies across 15+ therapeutic areas including IVD, novel device, first in human, RWE-based clinical trials, Investigator-Sponsored, and post-market studies

PUBLICATIONS 

• Gold MR, Aasbo JD, El-Chami MF, Niebauer M, Herre J, Prutkin JM, Knight BP, Kutalek S, Hsu K, Weiss R, Bass E, Husby M, Strivland TM, Burke C. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: clinical characteristics and perioperative results. Heart Rhythm. 2017 Oct 1;14(10):1456-63.
• Morse, D.C., Silva, E., Bartrom, J., Young, K., Bass E.J., Potter, D., Bieber, T. Improved bleeding scores using Gelfoam® Powder with incremental concentrations of bovine thrombin in a swine liver lesion model. J Thromb Thrombolysis 42, 352–359 (2016). https://doi.org/10.1007/s11239-016-1388-6
• Girasis C, Serruys PW, Onuma Y, Colombo A, Holmes D, Feldman TE, Bass EJ, Leadley K, Dawkins KD, Morice MC: 3-Dimensional Bifurcation Angle Analysis in Patients With Left Main Disease: A Substudy of the SYNTAX Trial (SYNergy Between Percutaneous Coronary Intervention With TAXus and Cardiac Surgery). J Am Coll Cardiol Intv. 2010 3:41-48.
• Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP, Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC, Colombo A, Bass E, Leadley K, Dawkins KD, van Es GA, Morel MA, Mohr FW. : Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009 May;5(1):50-6.
• Serruys PW, Morice MC, Kappetein P, Colombo A, Holmes DR, Mack MJ, Sta¨hle E, Feldman TE, van den Brand M, Bass EJ, Dyck NV, Leadley K, Dawkins K, Mohr FW: Percutaneous Coronary Intervention Versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med 2009;360:961–972.
• Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, Jett JR, Bonner JA, Sloan JA.: Quality of Life in 650 Patients with Small Cell and Non Small Cell Lung Cancer. Mayo Clin Proc. 2004 Aug; 79(8):1024-30.
• Taniguchi K, Yang P, Jett J, Bass E, Meyer R, Wang Y, Deschamps C, Liu W: Polymorphisms in the Promoter Region of the Neutrophil Elastase Gene Are Associated with Lung Cancer Development. Clinical Cancer Research; 8:1151, April 2002.
• Liu W, Deschamps C, Bass EJ, Yang P: The Role of Neutrophil Elastase in Lung Cancer Development. Proceedings American Association for Cancer Research Annual Meeting 2001 Mar;42:151.
• Yang P, Jett JR, Bass EJ, Couch FJ: Variant E1038G of the BRCA1 gene is associated with lung cancer in families with multiple breast/ovarian cancer relatives. Lung Cancer 29(Suppl 1): 227, September 2000.